Source comparison
CJC-1295 No DAC vs DAC: The Desensitization Risk
A critical concern in the CJC-1295 no DAC vs DAC comparison: GHRH receptor desensitization. When GHRH receptors are continuously stimulated (as with DAC’s 6-8 day half-life), the pituitary somatotroph cells can downregulate their receptor expression and intrac
This comparison does not assign a generated winner or score.
- A critical concern in the CJC-1295 no DAC vs DAC comparison: GHRH receptor desensitization. When GHRH receptors are continuously stimulated (as with DAC’s 6-8 day half-life), the pituitary somatotroph cells can downregulate their receptor expression and intracellular signaling — a protective mechanism against overstimulation. Published research documents that continuous GH secretagogue exposure produces diminishing GH responses over time, while pulsatile exposure maintains response magnitude.
- CJC-1295 no DAC’s short half-life inherently avoids this issue: 30 minutes of stimulation followed by hours of receptor rest before the next dose. The receptors reset between pulses, maintaining their sensitivity across multi-week research protocols. In the CJC-1295 no DAC vs DAC comparison, this desensitization resistance is a significant pharmacological advantage for sustained research programs.